Benzinga · Oct 6, 2026
WestPark Capital Initiates Coverage On Veru with Buy Rating, Announces Price Target of $28
WestPark Capital analyst Ed Arce initiates coverage on Veru (NASDAQ:VERU) with a Buy rating and announces Price Target of $28.
NASDAQ · VERU
Veru Inc.
Healthcare · Biotechnology
$2.19
Down-$0.04 (-1.79%)
Updated Nov 2, 2026, 1:39 PM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 37.07M
- P/E ratio
- -1.13
- Dividend yield
- 0.00%
- 52-week range
- $2.05 – $7.33
- Volume
- 78.95K
- Avg. volume
- 159K
Price performance · VERU
VERU price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
VERU closed at $2.19 after 20 trading sessions, down 14.12% for the selected period.
- Last close
- $2.19
- Period change
- -14.12%
- Period low
- $2.13
- Period high
- $2.55
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $2.25 | $2.26 | $2.1599 | $2.19 | 78.95K |
| Oct 29, 2026 | $2.27 | $2.33 | $2.22 | $2.23 | 56.94K |
| Oct 28, 2026 | $2.27 | $2.30 | $2.24 | $2.27 | 78.17K |
| Oct 27, 2026 | $2.22 | $2.37 | $2.22 | $2.28 | 157.71K |
| Oct 26, 2026 | $2.25 | $2.26 | $2.18 | $2.21 | 86.58K |
| Oct 23, 2026 | $2.29 | $2.32 | $2.22 | $2.24 | 122.59K |
| Oct 22, 2026 | $2.30 | $2.30 | $2.24 | $2.29 | 85.82K |
| Oct 21, 2026 | $2.37 | $2.41 | $2.28 | $2.30 | 99.81K |
| Oct 20, 2026 | $2.31 | $2.40 | $2.31 | $2.38 | 89.88K |
| Oct 19, 2026 | $2.30 | $2.35 | $2.27 | $2.31 | 88.14K |
| Oct 16, 2026 | $2.41 | $2.4827 | $2.27 | $2.30 | 306.5K |
| Oct 15, 2026 | $2.14 | $2.48 | $2.12 | $2.44 | 505.36K |
| Oct 14, 2026 | $2.26 | $2.29 | $2.11 | $2.13 | 275.21K |
| Oct 13, 2026 | $2.41 | $2.415 | $2.18 | $2.19 | 170.76K |
| Oct 12, 2026 | $2.44 | $2.45 | $2.40 | $2.405 | 85.52K |
| Oct 9, 2026 | $2.42 | $2.49 | $2.42 | $2.46 | 128.9K |
| Oct 8, 2026 | $2.44 | $2.5189 | $2.39 | $2.42 | 147.63K |
| Oct 7, 2026 | $2.42 | $2.54 | $2.41 | $2.46 | 203.38K |
| Oct 6, 2026 | $2.54 | $2.75 | $2.44 | $2.47 | 1.52M |
| Oct 5, 2026 | $2.51 | $2.62 | $2.50 | $2.55 | 88.77K |
Latest VERU news
The latest Smart Investors Daily articles mentioning VERU.
Stock researchCompany · Overview
Company
Market Activity
Research & News
VERU research
Overview
Company profile and research snapshot.
Company profile
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $4.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 6, 2026 | WestPark Capital | Buy | — |
| Jun 4, 2026 | Canaccord Genuity | Buy | — |
| May 15, 2026 | Oppenheimer | Outperform | — |
| Dec 18, 2025 | Canaccord Genuity | Buy | — |
| Aug 13, 2025 | Raymond James | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 8, 2026
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial
--New positive preclinical studies show that sabizabulin can overcome drug resistance to daraxonrasib with potent anticancer efficacy (IC50=18.2nM) in daraxonrasib resistant human pancreatic cancer cell line which is a drug concentration that can be achieved with current sabizabulin human dosing with good safety-- --Oral sabizabulin had a good safety profile and promising efficacy in previous first-in-man Phase 1b/2 clinical study of 80 subjects with castration resistant and taxane resistant met
Yahoo · Sep 2, 2026
Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference
MIAMI, FL, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will participate in a fireside chat at the upcoming 2026 Cantor Global Healthcare Conference, in New York City, New York, on September 9, 2026 from 2:10 pm – 2:40 pm Easte
SeekingAlpha · Aug 10, 2026
Veru Inc. (VERU) Q3 2026 Earnings Call Transcript
Veru Inc. (VERU) Q3 2026 Earnings Call August 10, 2026 8:00 AM EDTCompany ParticipantsSamuel Fisch - Executive Director of Investor Relations &...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
